CONVERTHER

The CONVERTHER project is a cross-border networking initiative focused on understanding precursor protein activation by proprotein convertases (PCs) under physiological conditions, particularly during aging and in treatment resistance in cancer. By integrating expertise in clinical research, chemistry, and spatial transcriptomics, the project aims to develop innovative therapeutic and prognostic strategies.

CONVERTHER is driven by a strong collaboration between the Signaling Lab (led by Iker Badiola) and the RYTME group (led by Majid Khatib). Together, they have successfully secured four Master's grants, two doctoral cotutelle grants, and one postdoctoral fellowship. Their partnership has also resulted in eight joint publications, including a 2025 publication in EMBO Molecular Medicine, as well as the submission of two patent applications, with ongoing efforts to secure new funding opportunities.

The project has established strong connections with leading health research institutes such as Biodonostia (Basque Country), the University of Montreal (Canada), and KU Leuven (Belgium) pioneering laboratories in the field of protein maturation and aging. Additionally, it collaborates with biotech companies like Nanokide Therapeutics (Bilbao) and XenoFish (Bordeaux). Scientifically, CONVERTHER is committed to advancing the study of protein activation by PCs, paving the way for novel prognostic and therapeutic applications.

Beyond research, the project places a strong emphasis on social and organizational initiatives to enhance cross-border collaboration. This includes knowledge exchange programs and outreach efforts to attract more partners, further strengthening the network and impact of the initiative.